Free Trial

Paradigm Biopharmaceuticals (PAR) News Today

Paradigm Biopharmaceuticals logo

PAR Latest News

PBIGF Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Ltd. (PBIGF) Receives a Buy from Bell Potter
PhosCo runs hard on Tunisian phosphate
Paradigm Biopharmaceuticals: Director’s Shareholding Update
Paradigm Biopharmaceuticals Targets Growth Amid Market Challenges
Vincerx Pharma Reports Third Quarter 2024 Financial Results
Paradigm Biopharma Advances Phase 3 Trials Amid Financial Prudence
Paradigm Biopharmaceuticals: Director Increases Shareholdings
Paradigm Biopharmaceuticals Plans New Securities Issuance
Biotech Alert: Searches spiking for these stocks today
Paradigm Biopharmaceuticals Boosts Confidence with Phase 3 Plans
Get Paradigm Biopharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for PAR and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PAR Media Mentions By Week

PAR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

PAR
News Sentiment

0.59

1.02

Average
Medical
News Sentiment

PAR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

PAR Articles
This Week

1

1

PAR Articles
Average Week

Get the Latest News and Ratings for PAR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Paradigm Biopharmaceuticals and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


This page (ASX:PAR) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners